Literature DB >> 19916703

Transforming growth factor-beta: a target for cancer therapy.

Ronan J Kelly1, John C Morris.   

Abstract

Transforming growth factor-beta (TGF-beta) is a pleiotropic growth factor that regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immune responses. TGF-beta demonstrates paradoxical action whereby it can function to suppress early tumorigenesis; however, it can also facilitate malignant transformation and stimulate tumor growth by manipulating a more hospitable environment for tumor invasion and the development of metastases. Given the integral role of TGF-beta in transformation and cancer progression, various components of the TGF-beta signaling pathway offer potentially attractive therapeutic targets for cancer treatment. This review focuses on the role of TGF-beta in cancer and discusses both small and large molecule drugs currently in development that target TGF-beta, its receptor and important down stream steps along its signaling pathway.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19916703     DOI： 10.3109/15476910903389920

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN： 1547-691X            Impact factor:   3.000


  17 in total

Review 1.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.

Authors:  Sri Navaratnam; Georgios Skliris; Gefei Qing; Shantanu Banerji; Ketan Badiani; Dongsheng Tu; Penelope A Bradbury; Natasha B Leighl; Frances A Shepherd; Janet Nowatzki; Alain Demers; Leigh Murphy
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

Review 3.  The role of cytokines in breast cancer development and progression.

Authors:  Marcela Esquivel-Velázquez; Pedro Ostoa-Saloma; Margarita Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta Ivonne Castro; Jorge Morales-Montor
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

4.  TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Authors:  Jeroen T Buijs; Keith R Stayrook; Theresa A Guise
Journal:  Cancer Microenviron       Date:  2011-07-12

5.  The role of TGF-β in bone metastasis: novel therapeutic perspectives.

Authors:  Jeroen T Buijs; Keith R Stayrook; Theresa A Guise
Journal:  Bonekey Rep       Date:  2012-06-06

Review 6.  MicroRNA and signal transduction pathways in tumor radiation response.

Authors:  Luqing Zhao; Xiongbin Lu; Ya Cao
Journal:  Cell Signal       Date:  2013-04-17       Impact factor: 4.315

7.  Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition.

Authors:  Yvonne Puplampu-Dove; Tal Gefen; Anugraha Rajagopalan; Darija Muheramagic; Brett Schrand; Eli Gilboa
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

8.  Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Authors:  Shanna A Arnold; Lee B Rivera; Juliet G Carbon; Jason E Toombs; Chi-Lun Chang; Amy D Bradshaw; Rolf A Brekken
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

9.  uPAR and cathepsin B shRNA impedes TGF-β1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway.

Authors:  V R Gogineni; R Gupta; A K Nalla; K K Velpula; J S Rao
Journal:  Cell Death Dis       Date:  2012-12-06       Impact factor: 8.469

10.  Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-dependent pathways in human lung carcinoma epithelial cells.

Authors:  Huey-Ming Lo; Jiunn-Min Shieh; Chih-Li Chen; Chih-Jen Tsou; Wen-Bin Wu
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.